↓ Skip to main content

Clinical Pharmacokinetics of Paracetamol

Overview of attention for article published in Clinical Pharmacokinetics, December 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

policy
2 policy sources
twitter
4 X users
patent
1 patent
facebook
1 Facebook page
wikipedia
5 Wikipedia pages

Citations

dimensions_citation
404 Dimensions

Readers on

mendeley
491 Mendeley
Title
Clinical Pharmacokinetics of Paracetamol
Published in
Clinical Pharmacokinetics, December 2012
DOI 10.2165/00003088-198207020-00001
Pubmed ID
Authors

John A. H. Forrest, J. A. Clements, L. F. Prescott

Abstract

In therapeutic doses paracetamol is a safe analgesic, but in overdosage it can cause severe hepatic necrosis. Following oral administration it is rapidly absorbed from the gastrointestinal tract, its systemic bioavailability being dose-dependent and ranging from 70 to 90%. Its rate of oral absorption is predominantly dependent on the rate of gastric emptying, being delayed by food, propantheline, pethidine and diamorphine and enhanced by metoclopramide. Paracetamol is also well absorbed from the rectum. It distributes rapidly and evenly throughout most tissues and fluids and has a volume of distribution of approximately 0.9L/kg. 10 to 20% of the drug is bound to red blood cells. Paracetamol is extensively metabolised (predominantly in the liver), the major metabolites being the sulphate and glucuronide conjugates. A minor fraction of drug is converted to a highly reactive alkylating metabolite which is inactivated with reduced glutathione and excreted in the urine as cysteine and mercapturic acid conjugates. Large doses of paracetamol (overdoses) cause acute hepatic necrosis as a result of depletion of glutathione and of binding of the excess reactive metabolite to vital cell constituents. This damage can be prevented by the early administration of sulfhydryl compounds such as methionine and N-acetylcysteine. In healthy subjects 85 to 95% of a therapeutic dose is excreted in the urine within 24 hours with about 4, 55, 30, 4 and 4% appearing as unchanged paracetamol and its glucuronide, sulphate, mercapturic acid and cysteine conjugates, respectively. The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min. Age has little effect on the plasma half-life, which is shortened in patients taking anticonvulsants. The plasma half-life is usually normal in patients with mild chronic liver disease, but its prolonged in those with decompensated liver disease.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 491 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 <1%
Canada 1 <1%
Belgium 1 <1%
Denmark 1 <1%
Nigeria 1 <1%
United States 1 <1%
Unknown 485 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 87 18%
Student > Master 69 14%
Student > Ph. D. Student 44 9%
Researcher 30 6%
Other 18 4%
Other 50 10%
Unknown 193 39%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 81 16%
Medicine and Dentistry 59 12%
Biochemistry, Genetics and Molecular Biology 35 7%
Chemistry 31 6%
Agricultural and Biological Sciences 24 5%
Other 58 12%
Unknown 203 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2024.
All research outputs
#2,231,088
of 25,709,917 outputs
Outputs from Clinical Pharmacokinetics
#78
of 1,613 outputs
Outputs of similar age
#19,903
of 288,078 outputs
Outputs of similar age from Clinical Pharmacokinetics
#10
of 390 outputs
Altmetric has tracked 25,709,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,613 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,078 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 390 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.